CHEN THOMAS C purchased $140K of NTHI

CHEN THOMAS C (CEO) purchased 36,259 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.86 ($3.85–$4.04, $0.14M total) across 2 trades over 2026-08-14 to 2026-08-17.

Original reporting
SEC EDGAR · CHEN THOMAS C
Published Aug 18, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTHI
Bullish
medium confidence
Mentioned
$NTHI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHIBullishLow
01

Why it matters

The CEO’s open-market purchase is a modest sentiment input but lacks accompanying guidance, financial results, or operational milestones in the filing text.

02

Market read

Traders may monitor for follow-on insider activity or subsequent company disclosures, but this filing alone is unlikely to drive a sustained repricing.

03

What to watch

The text does not state whether the purchase was funded by option exercises, prior sales, or personal tax planning, and it provides no 10b5-1 plan details.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for NEONC Technologies Holdings, Inc.

Company-level read

Ticker impact

$NTHIBullishMedium confidence
Context

SEC Form 4 shows CEO Chen Thomas C bought 36,259 shares of NEONC Technologies Holdings for about $140K at $3.85 to $4.04.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should fade without follow-on company news.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size is relatively small and there is no 10b5-1 plan or accompanying operational update in the text.

Market effects

No sector-wide read-through is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine liquidity or diversification rather than a strong valuation signal, especially without context on compensation or prior trading patterns.

Key entities

  • NEONC Technologies Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • CHEN THOMAS C

    CEO, officer/director/10% owner who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMedAI 8/10

NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov.

$NTHIMedAI 8/10

NeOnc to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting

NeOnc Technologies (NTHI) will present data on its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting. NEO100 data includes Phase 1/2a study and compassionate use results for recurrent IDH1-mutant astrocytoma. NEO212 data covers Phase 1 safety, pharmacokinetics, and early activity signals in TMZ-resistant recurrent GBM and brain metastases. Both posters are scheduled for November 13, 2026.

$NTHILowAI 8/10

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of invest